Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Growth in Short Interest

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 18,500 shares, a growth of 203.3% from the December 15th total of 6,100 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average trading volume of 10,700 shares, the days-to-cover ratio is currently 1.7 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.

Armata Pharmaceuticals Stock Down 3.3 %

NYSEAMERICAN:ARMP opened at $2.02 on Tuesday. Armata Pharmaceuticals has a 1-year low of $1.80 and a 1-year high of $4.48. The stock has a market capitalization of $73.08 million, a P/E ratio of -1.23 and a beta of 0.78.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.